Capillary electrophoresis‐mass spectrometry in impurity profiling of pharmaceutical products

Generally reversed‐phase high‐performance liquid chromatography (RP‐HPLC) methods are extensively applied during quality control of pharmaceutical products. Since capillary electrophoresis (CE) is based on a different separation principle and consequently results in a unique selectivity compared to RP‐HPLC, it can advantageously be used as an orthogonal technique. CE equipped with a mass spectrometer detector provides even more information that can be helpful for identification and structural elucidation purposes. CE‐MS was recently implemented in the method development approach to support impurity profiling of pharmaceutical products. In this paper the application of CE‐electrospray ionization (ESI)‐MS/MS to the impurity profiling of galantamine hydrobromide in stressed Reminyl® Extended Release (ER) capsules is discussed. Reminyl® ER samples were stressed at different storing conditions. The impurity profile of these samples was compared with the current RP‐HPLC and chiral CE method, but also with CE‐ESI‐MS/MS. The combination of these three methods provided valuable data that allowed understanding comprehensively the impurity profile of these samples. Two impurities were detected at concentrations lower than 0.05%, which did not occur in nonstressed samples. Chromatographic data and the fragmentation patterns of galantamine and related compounds were also examined for identification of these two degradation products.

[1]  S. Cherkaoui,et al.  Nonaqueous capillary electrophoresis‐electrospray‐ mass spectrometry for the analysis of fluoxetine and its related compounds , 2002, Electrophoresis.

[2]  C. Patterson,et al.  Clinical experience of galantamine in dementia: a series of case reports , 2003, Current medical research and opinion.

[3]  J. van der Greef,et al.  High-performance liquid chromatography with on-line coupled UV, mass spectrometric and biochemical detection for identification of acetylcholinesterase inhibitors from natural products. , 2000, Journal of chromatography. A.

[4]  J. Havel,et al.  Capillary zone electrophoresis determination of galanthamine in biological fluids and pharmaceutical preparatives: Experimental design and artificial neural network optimization , 1999, Electrophoresis.

[5]  M. Raskind Update on Alzheimer Drugs (Galantamine) , 2003, The neurologist.

[6]  C. Burandt,et al.  Evaluation of four Narcissus cultivars as potential sources for galanthamine production. , 1997, Planta medica.

[7]  S. Lilienfeld Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. , 2006, CNS drug reviews.

[8]  I. Yamboliev,et al.  Reversed-phase liquid chromatography for the determination of galanthamine and its metabolites in human plasma and urine. , 1987, Journal of chromatography.

[9]  M. De Meulder,et al.  Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinised plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[10]  K. Altria,et al.  Orthogonal separations of nicotine and nicotine‐related alkaloids by various capillary electrophoretic modes , 2004, Electrophoresis.

[11]  M. Farlow Clinical Pharmacokinetics of Galantamine , 2003, Clinical pharmacokinetics.

[12]  P. Westra,et al.  High-performance liquid chromatographic determination of galanthamine, a long-acting anticholinesterase drug, in serum, urine and bile. , 1983, Journal of chromatography.